Title : Histone deacetylase 2 (HDAC 2) expression in human breast cancer and its assositation with clinicopathological factors and patients survival
There is strong association with malignancy and histone deacetylases (HDAC) in humans. The histone deacetylase inhibitors (HDACI) are now tested as antitumor agents in various clinical trials. The aim of this study is to assess the clinical importance of HDAC-2 in breast cancer. Materials and Methods:118 breast cancer specimens were obtained from patients and were examined immunohistochemically. A statistical analysis was conducted in order to examine the relation between HDAC-2 and clinicopathological features and survival of the patients. Results: Higher levels of HDAC-2 expression were related to lobular histological type of cancer (p=0.004), grade III and stage III (p<0.001). In addition, the progression free survival and overall survival were shorter and negatively related to the over-expression of HDAC-2 respectively [HR: 3.32 (1.57-7.01), p=0.002], [HR: 2.56 (1.31-4.99), p=0.006]. Other factors correlated with worse survival were histological types different to ductal or lobular and stage of the disease (p<0.001). Conclusion: This study showed a possible relationship between HDAC-2 and breast cancer. Further studies need to be conducted in order to examine the value of HDAC-2 as a predictive tumor marker and therapeutic target against breast cancer.